Integra LifeSciences Holdings (IART) Earnings Analysis
Integra LifeSciences Holdings (IART) next reports earnings on 2026-07-29, consensus EPS 0.48 USD. Last quarter (2026-02-26) it beat with EPS 0.83 USD vs 0.79 USD est (+5.1%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E -2.90.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does IART next report earnings?
| Next earnings date | 2026-07-29 |
|---|---|
| Consensus EPS estimate | 0.48 USD |
| Revenue estimate | 0.42B |
IART earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-26 | 0.83 USD | 0.79 USD | +5.1% | Beat |
| 2025-10-30 | 0.54 USD | 0.43 USD | +25.6% | Beat |
| 2025-07-31 | 0.45 USD | 0.43 USD | +4.7% | Beat |
| 2025-05-05 | 0.41 USD | 0.43 USD | -4.7% | Miss |
| 2024-11-04 | 0.41 USD | 0.39 USD | +5.1% | Beat |
| 2024-07-29 | 0.63 USD | 0.62 USD | +1.6% | Beat |
Beat rate: 5/6 (83%) over reported quarters with consensus data.
IART valuation and analyst view
| Trailing P/E | -2.90 |
|---|---|
| Trailing EPS | -6.44304 USD |
| Price / book | 1.39 |
| Dividend yield | 0.00% |
| Market cap | 1.45B |
| Analyst consensus | Buy (11 buy / 11 hold / 4 sell) |
| Avg price target | 21 USD |
Related research pages
Frequently asked questions
When is Integra LifeSciences Holdings (IART)'s next earnings date?
Integra LifeSciences Holdings is next scheduled to report on 2026-07-29, with a consensus EPS estimate of 0.48 USD and revenue estimate of 0.42B.
Did IART beat earnings last quarter?
In its 2026-02-26 report, IART posted EPS of 0.83 USD versus a 0.79 USD estimate — a beat of 5.1%.
What is IART's earnings track record?
Over the last 6 reported quarters with consensus data, IART beat estimates 5 times (83%).
What is IART's current P/E ratio and EPS?
IART trades at a trailing P/E of -2.90 on trailing EPS of -6.443035178230303 USD.
What do analysts rate IART?
Analyst consensus is "Buy" across 26 ratings (0 strong buy, 11 buy, 11 hold, 4 sell, 0 strong sell). Average 12-month price target: 21 USD.